Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
11.09
-0.08 (-0.72%)
Mar 20, 2026, 1:11 PM EDT - Market open
Arvinas Revenue
In the year 2025, Arvinas had annual revenue of $262.60M, down -0.30%. Arvinas had revenue of $9.50M in the quarter ending December 31, 2025, a decrease of -83.95%.
Revenue (ttm)
$262.60M
Revenue Growth
-0.30%
P/S Ratio
2.72
Revenue / Employee
$1,067,480
Employees
246
Market Cap
709.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 262.60M | -800.00K | -0.30% |
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | 43.00M | 28.68M | 200.20% |
| Dec 31, 2018 | 14.32M | 6.75M | 89.00% |
| Dec 31, 2017 | 7.58M | 909.85K | 13.64% |
| Dec 31, 2016 | 6.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gyre Therapeutics | 116.59M |
| Theravance Biopharma | 107.46M |
| Lexicon Pharmaceuticals | 49.80M |
| Prime Medicine | 4.63M |
| Ocugen | 4.41M |
ARVN News
- 2 days ago - Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days - GlobeNewsWire
- 9 days ago - Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders - GlobeNewsWire
- 9 days ago - Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 25 days ago - Arvinas to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 - GlobeNewsWire
- 5 weeks ago - Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewsWire